Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the proposed study to examine the links among stress, craving for marijuana, and marijuana reminders, or "cues".
In this study, an agent called yohimbine will be used to produce stress-like responses. Yohimbine is known to cause stress response in studies of alcohol and other substance use disorders. This study intends to show it can be used to cause stress in marijuana users as well.
Part of this study will be conducted on a residential unit where participants will live for 7 nights over a 2-week period (4 consecutive nights the 1st week and 3 consecutive nights the 2nd week).
During that time, participants can't leave the unit unescorted or have visitors.
During the inpatient stay participants will participant in experimental sessions where they will be asked to smoke cigarettes containing either marijuana or placebo (a blank).
Participants will be asked to take capsules that could contain yohimbine or placebo (blank).
Participants will be asked to complete questionnaires and will have their vital signs (blood pressure, heart rate) monitored throughout each session.
Participants will be asked to participate in overnight sleep recordings, a polysomnogram (PSG).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Yohimbine 0mg X Cue Condition (neutral) | Placebo Comparator |
| |
| Yohimbine 0mg X Cue Condition (marijuana) | Placebo Comparator |
| |
| Yohimbine 20mg X Cue Condition (neutral) | Active Comparator |
| |
| Yohimbine 20mg X Cue Condition (marijuana) | Active Comparator |
| |
| Yohimbine 40mg X Cue Condition (neutral) | Active Comparator |
| |
| Yohimbine 40mg X Cue Condition (marijuana) | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Yohimbine | Drug | Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Marijuana Craving Visual Analog Scale (VAS) (Self-report measure) | Change is being assessed. Marijuana Craving VAS administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1220, 1245, 1300, 1315, 1345. | |
| Marijuana Craving Questionnaire (Self-report measure) | Change is being assessed. Marijuana Craving Quest.administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | |
| Questionnaire of Smoking Urges (Self-report measure) | Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | |
| Marijuana Rating Form (Self-report measure) | Change is being assessed. Marijuana Rating Form is administered 30 minutes after each smoking episode in the sampling session. | |
| Marijuana Withdrawal Checklist | Change is being assessed. Questionnaire is administered every morning and evening. | |
| Subjective Effects Scale Visual Analog Scale (VAS) (Self-report measure) | Change is being assessed. Subjective Effects Scale administered at baseline 0900.It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | |
| Positive & Negative Affect Schedule (Self-report measure) | Change is being assessed. Questionnaire is administered at baseline 0900. It will then be administered at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. | |
| Systolic blood pressure (physiological effects) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Candidates with the following conditions will be excluded:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Leslie Lundahl, PhD | Wayne State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tolan Park Medical Building | Detroit | Michigan | 48201 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D015016 | Yohimbine |
| ID | Term |
|---|---|
| D046948 | Secologanin Tryptamine Alkaloids |
| D026121 | Indole Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Change is being assessed. Systolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. |
| Diastolic blood pressure (physiological effects) | Change is being assessed. Diastolic blood pressure measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. |
| Heart rate (physiological effects) | Change is being assessed. Heart rate measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. |
| Core-body temperature (physiological effects) | Change is being assessed. Core-body temperature measured at baseline 0900. It will then be measure at 1000, 1030, 1100, 1200, 1410, 1430, 1500, 1530, 1600, 1630. |
| D007211 |
| Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D054836 | Indolizidines |
| D007212 | Indolizines |